Today: 19 April 2026
FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next
13 November 2025
2 mins read

UK Stocks Today (13 Nov 2025): FTSE 100 slips as 3i plunges, Aviva underwhelms; weak Q3 GDP and softer oil weigh on London

Summary

  • London’s blue-chip index pulled back after setting records earlier this week, with financials and energy leading losses.
  • Fresh UK GDP data showed just 0.1% growth in Q3, keeping December BoE cut odds elevated; sterling edged higher.
  • Stock-specific swings were sharp: 3i Group tumbled, Aviva fell after new targets, while Burberry and Wizz Air rallied; Persimmon rose on stronger forward sales.

Market snapshot

The FTSE 100 fell around 1% on Thursday, snapping its run of record closes, as weakness in financials and energy stocks overshadowed pockets of consumer and travel strength. Some ex‑dividend moves also tugged on the index into the close.

Macro drivers: growth, sterling, and rate‑cut odds

The UK economy expanded by 0.1% in Q3—half the pace economists expected—with September output dented by the Jaguar Land Rover cyberattack that slammed car production. Markets responded by leaning further toward a December rate cut from the Bank of England, with rate‑cut probabilities hovering in the ~80% area. The pound nonetheless ticked up about 0.2% versus the dollar.

Biggest movers on the day

3i Group (III) — sharp sell‑off
The private‑equity investor skidded more than 14%—and as much as 17% at one point—as management struck a cautious tone on new deals and October trading cooled at Action, its key retail holding. It was one of the steepest single‑day declines in years.

Aviva (AV.) — targets raise… but shares fall
Aviva unveiled upgraded medium‑term goals—~11% EPS CAGR (2025–2028), >£7bn cash remittances (2026–2028), and £225m cost synergies from the Direct Line integration—with capital synergies of >£0.5bn. The market reaction was cool, sending the shares lower on the day despite guidance to resume larger buybacks in 2026.

Burberry (BRBY) — first growth in two years
Burberry’s early turnaround under CEO Joshua Schulman delivered its first quarter of comparable sales growth in two years (up 2%), lifting the stock more than 8% as China returned to growth and the brand refocused on heritage outerwear.

Wizz Air (WIZZ) — profits up, shares climb
Wizz Air reported a ~26% first‑half operating profit jump and cut capacity/revenue ambitions for winter to protect yields; investors focused on the profit beat and operational progress, pushing the shares higher.

Homebuilders and housing — split signals
RICS’ October survey showed buyer enquiries and agreed sales weakening into the budget, a sign of softer demand. Even so, Persimmon rose after reporting a 15% rise in forward sales to £2.79bn and reaffirming guidance.

Miners and commodities — gold helps, oil hurts
Precious‑metals miners outperformed as gold touched a three‑week high on firmer Fed cut bets after the U.S. government reopened, while energy lagged as oil prices drifted on U.S. inventory builds and a swelling‑surplus narrative into 2026.

Why it mattered today

Two forces pulled London in opposite directions. Domestically, tepid growth (and a softer housing pulse) kept rate‑cut hopes alive—a tailwind for rate‑sensitives—but sterling’s bounce and the energy slump weighed on index heavyweights. Corporate‑specific news then amplified moves: 3i and Aviva knocked financials, while Burberry and Persimmon steadied consumer‑facing pockets.

The policy and data path ahead

  • Autumn Budget: 26 November 2025 — fiscal choices are central to growth and sector sentiment.
  • Inflation (ONS): October CPI lands 19 November, 07:00 — key input for December BoE.
  • Bank of England decision:18 December 2025 — markets currently price high odds of a cut.

Stock‑by‑stock, sector‑by‑sector digest for 13/11/2025

  • Financials: 3i’s slump dominated; life insurers tracked lower with Aviva softer despite upgraded targets.
  • Energy: Oil majors underperformed as Brent held near the low‑60s after larger‑than‑expected U.S. crude builds and surplus forecasts.
  • Consumer/Luxury:Burberry outperformed on returning growth; strength here offset some broader risk‑off tone.
  • Travel:Wizz Air rallied on improved profitability despite a trimmed winter outlook.
  • Housing: RICS survey cooled, but Persimmon’s order book and forward sales supported the group.

Outlook
With growth flat and the BoE poised to act, near‑term UK equity direction likely hinges on: (1) how the Autumn Budget balances consolidation with growth incentives; (2) the inflation print next week; and (3) global risk appetite as oil searches for a floor and gold stays bid on policy hopes. In the meantime, dispersion will stay high—company news is doing the heavy lifting.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears
Previous Story

German Stock Market Today, 13 Nov 2025: DAX Closes 1.39% Lower at 24,041 as Siemens Slumps; Merck Rises, Allianz Lifts Guidance

Tokyo Stock Exchange Surges to Record Highs on AI Boom – Inside the Nov 3, 2025 Rally
Next Story

Japan Stock Market Today: Nikkei 225 Rises as Yen Weakens and Topix Hits Record High – November 13, 2025

Go toTop